Navigation Links
Amgen To Present At The UBS Global Life Sciences Conference
Date:5/16/2013

THOUSAND OAKS, Calif., May 16, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square in New York City, beginning at 10:00 a.m. Eastern Daylight Time. Joseph P. Miletich , M.D., Ph.D., senior vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss , 805-313-6151 (media)
Arvind Sood , 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

 


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
2. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
3. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
4. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
5. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
6. Amgen Announces Webcast of 2013 First Quarter Financial Results
7. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
8. Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference
9. Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
10. Selexis Announces Expansion of R&D License Agreement with Amgen
11. Amgen Outlines Long-Term Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2019)... ... June 19, 2019 , ... INDIGO Biosciences, Inc. (INDIGO), ... announced the addition of the Human MDR-1 / P-Glycoprotein Drug Interaction Assay ... and allows researchers to perform critical toxicology testing previously available only through contract ...
(Date:6/18/2019)... ... June 18, 2019 , ... Officials with American Physician ... are pleased to announce the acquisition of Leading Edge Medical Associates (LEMA), a ... physicians and 9 advanced practice clinicians care for 115,000 emergency department patients annually ...
(Date:6/16/2019)... ... June 15, 2019 , ... Lycotec Ltd, a Cambridge ... study on its new prebiotic, LycoBiotic™, which is 1,000 – 4,000 stronger than ... which were based on a proprietary composition of GA lycopene, specially developed for ...
Breaking Medicine Technology:
(Date:6/16/2019)... ... June 15, 2019 , ... All families go through tough times. When parents ... and lack of a support network, they may be unable to care for their ... the home and place them with a relative, familiar caregiver or foster family while ...
(Date:6/14/2019)... ... June 14, 2019 , ... ... Pink Bag Event® scheduled for Saturday, July 13th. UBCF is thrilled to return ... directly impacted by breast cancer. This second event was added after an overwhelming ...
(Date:6/13/2019)... ... June 13, 2019 , ... Endometriosis is a painful, inflammatory disease that occurs when ... , Painful periods , Heavy bleeding , Irregular menstruation , ... , Women’s Excellence uses the latest and newest treatment protocols in dealing with the ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... 30 Second Test (BL30SEC) has been accepted by the 2019 National Conference of ... Appendix N requirements. , The Charm BL30SEC test was validated by third ...
(Date:6/13/2019)... ... ... Hard money lenders like Monroe Funding Corporation are able to respond and approve ... If the documentation and collateral are immediately available, it’s possible to receive approval and ... with a traditional lender, which allows loans to be customized and adjusted based on ...
Breaking Medicine News(10 mins):